StreetInsider.com News Articles

Trevi Therapeutics (TRVI) PT Raised to $30 at Stifel

Fri, 08 May 2026 08:43:41 -0400

Stifel analyst Annabel Samimy raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $30.00 (from $18.00) while maintaining a Buy rating.

Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.

Thu, 07 May 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260507/26455660.html

Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.

Thu, 07 May 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260507/26455660.html

Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260506/26441784.html

Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260506/26441784.html

Trevi Therapeutics (TRVI) PT Raised to $21 at B.Riley

Wed, 06 May 2026 09:21:09 -0400

B.Riley analyst Mayank Mamtani raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $21.00 (from $16.00) while maintaining a Buy rating.

Trevi Therapeutics (TRVI) PT Raised to $20 at Morgan Stanley

Wed, 06 May 2026 08:15:59 -0400

Morgan Stanley analyst Judah Frommer raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $20.00 (from $18.00) while maintaining a Overweight rating.

Trevi Therapeutics (TRVI) PT Lowered to $23 at Needham

Wed, 06 May 2026 07:21:44 -0400

Needham analyst Serge Belanger lowered the price target on Trevi Therapeutics (NASDAQ: TRVI) to $23.00 (from $24.00) while maintaining a Buy rating.

Stifel Reiterates Buy Rating on Trevi Therapeutics (TRVI)

Wed, 06 May 2026 00:49:17 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $18.00 price target on Trevi Therapeutics (NASDAQ: TRVI)

The analyst comments: “We reiterate our Buy rating on TRVI, $18 TP. Following a productive EOP2 meeting with FDA, TRVI will initiate its pivotal program for Haduvio in IPF-CC this quarter, based on a prudent two trial design with primary endpoint readouts at 12 and 24 weeks (first data expected 2027). We think the two-trial pivotal design was prudent in light of still-untested one-trial approach proposed by FDA. TRVI’s next regulatory meeting will serve to solidify clinical and regulatory plans to expand into non-IPF

Form 10-Q Trevi Therapeutics, Inc. For: Mar 31

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434724.html

Form 10-Q Trevi Therapeutics, Inc. For: Mar 31

Tue, 05 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260505/26434724.html

Form 8-K Trevi Therapeutics, Inc. For: May 05

Tue, 05 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260505/26434638.html

Form 8-K Trevi Therapeutics, Inc. For: May 05

Tue, 05 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260505/26434638.html

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Tue, 05 May 2026 16:05:00 -0400

Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement

Clinical development plans remain on track across all chronic cough indications